These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 27875356)

  • 1. Corticosteroids and Thiopurines, But Not Tumor Necrosis Factor Antagonists, are Associated With Cytomegalovirus Reactivation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Shukla T; Singh S; Tandon P; McCurdy JD
    J Clin Gastroenterol; 2017; 51(5):394-401. PubMed ID: 27875356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.
    Deepak P; Stobaugh DJ; Ehrenpreis ED
    J Gastrointestin Liver Dis; 2013 Sep; 22(3):269-76. PubMed ID: 24078983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of infections associated with biological treatment in inflammatory bowel disease.
    Andersen NN; Jess T
    World J Gastroenterol; 2014 Nov; 20(43):16014-9. PubMed ID: 25473153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seroprevalence of Epstein-Barr Virus, Cytomegalovirus, and Polyomaviruses in Children with Inflammatory Bowel Disease.
    Hradsky O; Copova I; Zarubova K; Durilova M; Nevoral J; Maminak M; Hubacek P; Bronsky J
    Dig Dis Sci; 2015 Nov; 60(11):3399-407. PubMed ID: 26091801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Singh S; Facciorusso A; Dulai PS; Jairath V; Sandborn WJ
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):69-81.e3. PubMed ID: 30876964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.
    McKenna MR; Stobaugh DJ; Deepak P
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):267-71. PubMed ID: 25267954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn's disease.
    Ma C; Walters B; Fedorak RN
    World J Gastroenterol; 2013 Jun; 19(21):3347-51. PubMed ID: 23745038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease.
    Chupin A; Perduca V; Meyer A; Bellanger C; Carbonnel F; Dong C
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1289-1297. PubMed ID: 32840893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists.
    Shah R; Ho EY; Kramer JR; Richardson P; Sansgiry S; El-Serag HB; Hou JK
    Dig Dis Sci; 2018 Jun; 63(6):1551-1557. PubMed ID: 29663266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased risk of pneumonia among patients with inflammatory bowel disease.
    Long MD; Martin C; Sandler RS; Kappelman MD
    Am J Gastroenterol; 2013 Feb; 108(2):240-8. PubMed ID: 23295276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus reactivation in inflammatory bowel disease: an uncommon occurrence related to corticosteroid dependence.
    Hissong E; Chen Z; Yantiss RK
    Mod Pathol; 2019 Jul; 32(8):1210-1216. PubMed ID: 30952971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines.
    Wisniewski A; Kirchgesner J; Seksik P; Landman C; Bourrier A; Nion-Larmurier I; Marteau P; Cosnes J; Sokol H; Beaugerie L;
    United European Gastroenterol J; 2020 Apr; 8(3):303-313. PubMed ID: 32529821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus and ulcerative colitis: Place of antiviral therapy.
    Pillet S; Pozzetto B; Roblin X
    World J Gastroenterol; 2016 Feb; 22(6):2030-45. PubMed ID: 26877608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.
    Kirchgesner J; Lemaitre M; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
    Gastroenterology; 2018 Aug; 155(2):337-346.e10. PubMed ID: 29655835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of infections with biological agents.
    Kopylov U; Afif W
    Gastroenterol Clin North Am; 2014 Sep; 43(3):509-24. PubMed ID: 25110256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complications of biologics in inflammatory bowel disease.
    Sousa P; Allez M
    Curr Opin Gastroenterol; 2015 Jul; 31(4):296-302. PubMed ID: 26039721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nocardia infections among immunomodulated inflammatory bowel disease patients: A review.
    Abreu C; Rocha-Pereira N; Sarmento A; Magro F
    World J Gastroenterol; 2015 Jun; 21(21):6491-8. PubMed ID: 26074688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus disease in inflammatory bowel disease: epidemiology and disease characteristics in a large single-centre experience.
    Bontà J; Zeitz J; Frei P; Biedermann L; Sulz MC; Vavricka SR; Scharl S; Fried M; Rogler G; Scharl M
    Eur J Gastroenterol Hepatol; 2016 Nov; 28(11):1329-34. PubMed ID: 27482785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic-Induced Infections in Inflammatory Bowel Disease: The TNF-α Antagonists.
    McConachie SM; Wilhelm SM; Bhargava A; Kale-Pradhan PB
    Ann Pharmacother; 2018 Jun; 52(6):571-579. PubMed ID: 29363355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.